C
Claire N. Harrison
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 511
Citations - 24605
Claire N. Harrison is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Ruxolitinib & Myelofibrosis. The author has an hindex of 66, co-authored 424 publications receiving 19843 citations. Previous affiliations of Claire N. Harrison include St Thomas' Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
Jason Gotlib,Nashat Y. Gabrail,Casey O'Connell,Regina Garcia-Delgado,Timothy Sbardellati,Wayne Rothbaum,Jesse McGreivy,Claire N. Harrison,Jean-Jacques Kiladjian +8 more
TL;DR: This randomized, open-label study aims to evaluate the efficacy, safety, and pharmacokinetics of KRT-232 compared with ruxolitinib in up to 320 patients with phlebotomy-dependent PV.
Journal ArticleDOI
Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts
Claire N. Harrison,Nicolaas Schaap,Alessandro M. Vannucchi,Jean-Jacques Kiladjian,Francesco Passamonti,Sonja Zweegman,Moshe Talpaz,Srdan Verstovsek,Torsten Gerike,Shelonitda Rose,Jun Zhang,Tymara Berry,Carrie Brownstein,Ruben A. Mesa +13 more
Journal ArticleDOI
Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition.
Leslie Padrnos,Robyn M. Scherber,H. Geyer,Blake T. Langlais,Amylou C. Dueck,Heidi E. Kosiorek,Zhenya Senyak,Matthew M. Clark,Michael Boxer,Mary Cotter,Claire N. Harrison,Cynthia M. Stonnington,Yonas E. Geda,Yonas E. Geda,Ruben A. Mesa +14 more
TL;DR: This data indicates that depression may be present in over a quarter of Philadelphia chromosome negative myeloproliferative neoplasms patients, but no studies have evaluated the relationship between depression and other variables such as symptoms.
Journal ArticleDOI
EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 109/L to 99 × 109/L) at Baseline
Alessandro M. Vannucchi,Heinz Gisslinger,Claire N. Harrison,Haifa Kathrin Al-Ali,Ester Pungolino,Jean-Jacques Kiladjian,Françoise Boyer-Perrard,Franck E. Nicolini,Shuyuan Mo,Edric Atienza,Prashanth Gopalakrishna,Peter A. W. te Boekhorst +11 more
TL;DR: Evaluating the safety of RUX and establishing a maximum safe starting dose (MSSD) in pts with low PLTs to show that starting at 5 mg bid with dose escalation to ≥ 10 mg bid offered similar benefits to patients receiving RUX showed similar benefits.
Journal ArticleDOI
Equivalence of BCSH and WHO diagnostic criteria for ET
TL;DR: It is necessary to select patients suitable for bone marrow transplantation based on prior history and once they provide informed consent for surgery, theurden of disease may increase and the need for additional treatments may increase.